Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.63 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.62 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.62 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.62 |
| ▸ | NPY1R | P25929 | 3/20 | 0.60 |
| ▸ | NPY2R | P49146 | 3/20 | 0.60 |
| ▸ | NPY4R | P50391 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508679 | 0.97 | GHSR (0.64) | GHSRERAP1ERAP2LNPEPNPY1R | |
| SCHEMBL29508662 | 0.96 | GHSR (0.63) | GHSRERAP1ERAP2LNPEPNPY1R | |
| SCHEMBL31731732 | 0.96 | GHSR (0.62) | GHSRERAP1ERAP2LNPEPNPY1R | |
| SCHEMBL29578675 | 0.96 | NPY1R (0.66) | GHSRERAP1ERAP2LNPEPNPY1R | |
| SCHEMBL29577431 | 0.96 | NPY1R (0.66) | GHSRERAP1ERAP2LNPEPNPY1R | |
| SCHEMBL29508714 | 0.95 | GHSR (0.64) | GHSRERAP1ERAP2LNPEPNPY1R | |
| SCHEMBL31451018 | 0.95 | GHSR (0.67) | GHSR | |
| SCHEMBL29370555 | 0.95 | GHSR (0.67) | GHSR | |
| SCHEMBL29779862 | 0.94 | IL1RN (0.65) | GHSRERAP1ERAP2OPRM1OPRD1 | |
| SCHEMBL29405001 | 0.94 | GHSR (0.68) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | TVA (ABC), LLC (US) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | GHSR 19/4885ERAP1 1001/4885ERAP2 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.